Corient Private Wealth LLC Has $9.45 Million Stock Position in Alnylam Pharmaceuticals, Inc. $ALNY

Corient Private Wealth LLC lowered its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 39.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 23,763 shares of the biopharmaceutical company’s stock after selling 15,629 shares during the quarter. Corient Private Wealth LLC’s holdings in Alnylam Pharmaceuticals were worth $9,448,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently bought and sold shares of the business. Groupama Asset Managment raised its holdings in Alnylam Pharmaceuticals by 160.4% during the third quarter. Groupama Asset Managment now owns 4,032,082 shares of the biopharmaceutical company’s stock valued at $18,610,000 after buying an additional 2,483,697 shares in the last quarter. Norges Bank bought a new position in shares of Alnylam Pharmaceuticals in the 4th quarter valued at approximately $895,816,000. Arrowstreet Capital Limited Partnership lifted its holdings in Alnylam Pharmaceuticals by 698.8% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 1,355,609 shares of the biopharmaceutical company’s stock worth $618,158,000 after purchasing an additional 1,185,909 shares during the last quarter. Qube Research & Technologies Ltd bought a new stake in Alnylam Pharmaceuticals during the third quarter worth approximately $369,943,000. Finally, AQR Capital Management LLC grew its holdings in Alnylam Pharmaceuticals by 295.2% during the third quarter. AQR Capital Management LLC now owns 744,008 shares of the biopharmaceutical company’s stock valued at $336,009,000 after purchasing an additional 555,759 shares during the last quarter. 92.97% of the stock is currently owned by institutional investors.

Alnylam Pharmaceuticals Trading Up 2.0%

Alnylam Pharmaceuticals stock opened at $294.06 on Thursday. The business has a 50 day moving average price of $298.02 and a two-hundred day moving average price of $333.52. The company has a quick ratio of 3.06, a current ratio of 3.13 and a debt-to-equity ratio of 0.94. Alnylam Pharmaceuticals, Inc. has a 12 month low of $273.11 and a 12 month high of $495.55. The stock has a market cap of $39.26 billion, a price-to-earnings ratio of 80.34 and a beta of 0.29.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $1.99 earnings per share for the quarter, topping the consensus estimate of $0.87 by $1.12. The company had revenue of $1.17 billion for the quarter, compared to analyst estimates of $1.12 billion. Alnylam Pharmaceuticals had a return on equity of 85.76% and a net margin of 11.72%.Alnylam Pharmaceuticals’s revenue for the quarter was up 96.4% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.44) EPS. As a group, equities analysts forecast that Alnylam Pharmaceuticals, Inc. will post 7.47 EPS for the current year.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the stock. Royal Bank Of Canada reduced their price objective on shares of Alnylam Pharmaceuticals from $450.00 to $445.00 and set an “outperform” rating for the company in a research note on Friday, May 1st. Jefferies Financial Group restated a “hold” rating and set a $330.00 price target (down from $522.00) on shares of Alnylam Pharmaceuticals in a report on Monday, March 16th. Truist Financial dropped their price objective on Alnylam Pharmaceuticals from $515.00 to $505.00 and set a “buy” rating on the stock in a research note on Monday, April 13th. Chardan Capital restated a “buy” rating and set a $425.00 target price on shares of Alnylam Pharmaceuticals in a research note on Wednesday, March 25th. Finally, Wells Fargo & Company lifted their price target on Alnylam Pharmaceuticals from $376.00 to $377.00 and gave the stock an “equal weight” rating in a research report on Friday, May 1st. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Alnylam Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $463.13.

Insiders Place Their Bets

In other Alnylam Pharmaceuticals news, Director David E. I. Pyott sold 3,830 shares of Alnylam Pharmaceuticals stock in a transaction on Monday, June 1st. The shares were sold at an average price of $299.18, for a total transaction of $1,145,859.40. Following the sale, the director owned 1,582 shares in the company, valued at $473,302.76. The trade was a 70.77% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Melissa Mclaughlin sold 2,286 shares of the stock in a transaction on Monday, April 6th. The shares were sold at an average price of $330.42, for a total transaction of $755,340.12. Following the completion of the transaction, the insider owned 9,443 shares of the company’s stock, valued at approximately $3,120,156.06. This represents a 19.49% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 7,740 shares of company stock worth $2,420,214 in the last quarter. Corporate insiders own 0.86% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.